Other languages Lytix Biopharma

Equities

LYTIX

NO0010405780

Real-time Oslo Bors Other stock markets 06:32:44 10/05/2024 pm IST			5-day change	1st Jan Change
5.48 ^NOK	+0.37%		-6.48%	+12.76%

25/04	Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	CI
10/04	Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	25/04
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	10/04
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy	05/01
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology	11/12
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Lytix Biopharma AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/23/31
Lytix Biopharma Completes Patient Enrollment for LTX-315 Trial	28/23/28
Lytix Biopharma AS Completes Recruitment of 20 Patients in the ATLAS-IT-05 Trial	28/23/28
Lytix Biopharma's Licensing Partner Verrica Pharmaceuticals Inc. Reports Interim Phase 2 Data with LTX-315	11/23/11
Lytix Biopharma AS Announces Presentation of Interim Data from ATLAS-IT-05 Study at ESMO 2023	20/23/20
Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Lytix Biopharma Elects New Chair	19/23/19
Lytix Biopharma AS Appoints Marie Ann Roskrow as New Chairman of the Board	18/23/18
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2022	16/23/16
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	16/23/16
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/22/17
Lytix Biopharma AS Announces Expansion of the ATLAS-IT-05 Study to Europe	14/22/14
Lytix Biopharma Announces Site Activation for the ATLAS-IT-05 Study in Three European Countries	14/22/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lytix Biopharma

Equities

LYTIX

NO0010405780

Other languages

Filters